Biotheryx, Inc.

Biotheryx, Inc. is a biopharmaceutical company founded in 2007, with a focus on developing innovative small molecule targeted protein degraders (TPDs) for the treatment of various diseases, initially concentrating on cancer. The company's proprietary PRODEGY platform, developed by members of the founding and scientific teams, has led to the creation of their lead product candidate, BTX-1188. This product is a dual-targeting molecular glue degrader of GSPT1 and IKZF1/3 and is currently undergoing Phase 1/2 clinical trials in AML and solid tumor patients. Biotheryx's pipeline also includes degraders of SOS1 for KRAS mutant cancers and CDK2/4/6 for solid tumors, with plans to advance three new programs into clinical development over the next three years. The company recently received a $6.00M Corporate Round investment on 05 April 2023 from Incyte, highlighting investor confidence in Biotheryx's approach and potential. With its promise to degrade proteins, save lives, and lead the next-generation targeted protein degradation, Biotheryx is poised to make significant contributions to the biotechnology and healthcare industries. For further details, visit www.biotheryx.com.